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Chronic myeloid leukaemia is typically characterised by the presence of dysregulated BCR–ABL tyrosine kinase activity, which
is central to the oncogenic feature of being resistant to a wide range of cytotoxic agents. We have investigated whether the
inhibition of this tyrosine kinase by the novel compound STI571 (formerly CGP57148B) would render K562, KU812 cell lines
and chronic myeloid leukaemia-progenitor cells sensitive to induction of cell kill. Proliferation assays showed STI571 to be an
effective cytotoxic agent in chronic myeloid leukaemia-derived cell lines (IC50 on day 5 of 4.6 mgm l
71 and 3.4 mgm l
71 for
K562 and KU812 respectively) and in leukaemic blast cells (per cent viability on day 3 at 4 mgm l
71: 55.5+8.7 vs 96.4+3.7%).
STI571 also appeared to speciﬁcally target bcr–abl expressing cells, as results from colony forming assays using the surviving
cell fraction from STI571-treated peripheral CD34
+ chronic myeloid leukaemia blast cells, indicated a reduction in the
expansion of colonies of myeloid lineage, but no effect on normal colony formation. Our data also showed synergy between
STI571 and other anti-leukaemic agents; as an example, there were signiﬁcant increases in per cent cell kill in cell lines cultured
with both STI571 and etoposide compared to the two alone (per cent cell kill on day 3: 73.7+11.3 vs 44.5+8.7 and
17.8+7.0% in cultures with STI571 and etoposide alone respectively; P50.001). This study conﬁrms the central oncogenic
role of BCR–ABL in the pathogenesis of chronic myeloid leukaemia, and highlights the role of targeting this tyrosine kinase as
a useful tool in the clinical management of the disease.
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We have previously demonstrated the human chronic myeloid
leukaemic (CML) cell lines K562 and KU812 to be relatively resis-
tant to apoptosis induced by a wide range of anti-cancer agents,
including etoposide and cisplatin (Liu et al, 2002). Although the
exact mechanism of this aberrant suppression of apoptosis is
poorly understood, studies have highlighted the importance of
the Philadelphia chromosome present in these cell types (reviewed
in Holyoake, 2001). This balanced reciprocal translocation fuses
together the c-abl proto-oncogene from chromosome 9 to the
breakpoint-cluster region of the bcr gene on chromosome 22
(Nowell and Hungerford, 1960; Rowley, 1973).
Mammalian C-ABL belong to a family of tyrosine kinases (TK),
the biological function of which remains unclear, although it has
been shown to have a diverse role in the regulation of multiple
cellular processes including transcription, DNA repair and the cell
cycle. The bcr–abl gene created by this inter-chromosomal
exchange encodes one of two fusion proteins, p185 and p210, that
display elevated and dysregulated TK activity, and forms the funda-
mental mechanism underlying CML positive cells. The p210 form
of BCR–ABL is seen in 95% of all patients with CML and up to
20% of adult patients with acute lymphocytic leukaemia (ALL)
(Bartram et al, 1983; Shtivelman et al, 1985), whereas the p185
form is seen in 5–10% of de novo ALL (Hermans et al, 1987; Clark
et al, 1988). Currently, allogeneic bone marrow transplantation is
the only proven curative therapy for CML, and the cure rate for
approximately one-third of CML patients that are eligible is 70–
90% (Kantarjian et al, 1993; Goldman, 1994). Interferon-a has
been reported to induce both sustained remissions (Sanchez et al,
1992) and prolong survival (Allan et al, 1994; NCI, 1997), however,
this is not a curative therapy. As it is generally accepted that TK
activity is required for the transforming ability of BCR–ABL
fusion-proteins (Lugo et al, 1990; Oda et al, 1995), a speciﬁc inhi-
bitor of TK function may represent a possible therapy for CML
and other bcr–abl positive leukaemias (Levitzki and Gazit, 1995).
One such class of TK inhibitors, referred to as tyrphostins, was
reported in the late 1980s (Yaish et al, 1988). Synthesised and
developed by a team in Israel, this novel class of compounds
was one of the ﬁrst to demonstrate p210 BCR–ABL TK inhibi-
tory properties, inducing cell kill in K562 cells (Anaﬁ et al,
1993). Recently, a novel 2-phenylaminopyrimidine derivative
named STI571 (formerly CGP57148B) has been reported, which
has improved speciﬁcity over the tyrphostins (Buchdunger et al,
1996; Druker et al, 1996). The compound was designed in 1996
by using the known structure of the ATP binding site of protein
kinases, and early biochemical screening showed STI571 to be a
potent inhibitor of BCR–ABL TK (IC50: 0.025 mM in vitro for
substrate phosphorylation). The results of cell line experiments
showed STI571 was capable of selectively and effectively inhibiting
the growth of bcr–abl positive cell lines (K562), whilst appearing
to have no affect on the proliferation of cell lines expressing other
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www.bjcancer.comTKs such as v-src (Druker et al, 1996). Similarly, colony-forming
assays also showed STI571 speciﬁcally inhibited the formation of
bcr–abl positive colonies by 90%, without affecting bcr–abl nega-
tive cells. In vivo data from murine experiments showed limited
activity at 410 mg kg
71; however, complete cures were not
reported. A number of phase I trials by Druker investigating
the efﬁcacy of STI571 in CML patients presenting at different
stages of the disease have shown good results. The initial study
included 83 patients with chronic phase disease who had failed
interferon-a therapy. The minimum effective dose was 300 mg,
producing complete haematological response in 98% (Druker et
al, 2001a). In another study of 233 patients with accelerated phase
CML, there were responses in 91% of patients treated, of which
63% were complete responses (Mauro and Druker, 2001). The
effectiveness of STI571 in the earlier stages of the disease resulted
in an expansion of these phase I studies to include CML patients
in myeloid and lymphoid blast crisis and patients with relapsed or
non-responsive BCR–ABL positive ALL. Responses occurred in 21
of 38 patients (55%) with myeloid blast crisis, and in 14 of 21
patients (70%) with lymphoid crisis or ALL (Druker et al,
2001b). Phase II and III studies are currently ongoing in newly
diagnosed patients.
This report details the in vitro effects of single-agent STI571 in
CD34
+ CML stem cells and CML-derived cell lines. Interactions
with the cytotoxic agents etoposide and cytarabine were also
assessed.
MATERIALS AND METHODS
TK inhibitor – STI571
The 2-phenylaminopyrimidine derivative designated STI571 was
kindly provided by Novartis Inc (Basel, Switzerland). A 1 mg ml
71
(&1.7 mM) stock solution in dimethylsuphoxide (DMSO; Sigma
Ltd, Dorset, UK) was prepared from the total of 10 mg provided,
of which appropriate working dilutions were made prior to each
experiment.
In vitro analysis – cell lines
K562 and KU812 cell lines were maintained in RPMI-1640 medium
supplemented with 10% FBS and 1% PS, in a humidiﬁed atmo-
sphere with 5% CO2 in air at 378C.
To study the effect of a continuous exposure, K562 and KU812
cells (2610
5 cell ml
71) growing exponentially were cultured for 5
days with STI571 at a range of concentrations between 0–
5 mgm l
71. Aliquots were removed daily for assessment of viability
by Trypan blue exclusion and cell cycle distribution including
apoptosis.
To study the effect of STI571 in combination with existing
cytotoxic agents, K562 and KU812 cells (2610
5 cell ml
71) were
cultured for 5 days with either 0.8 mM etoposide or 40 nM cytar-
abine (both Sigma) in the presence or absence of 4 mgm l
71
STI571 (&IC50). Cell counting and cell cycle analysis were
performed daily. As these cell lines were resistant to a continu-
ous exposure to these cytotoxic agents, IC50 values for viability
could not be determined. Therefore, the concentrations were
chosen based on their ability to inhibit cell proliferation by
about 50%.
All cell counts were expressed as population doublings (PD)
using the following formula:
PD 
Log
8
:CCn
CCo
9
;
Log2
1
where n=day of study.
Ex vivo analysis – CD34
+/CML-positive blast cells
CD34
+ stem cells from the peripheral blood of four patients with
CML in blast crisis were harvested by using anti-CD34
+ conjugated
magnetic beads. All patients gave informed consent to the collec-
tion of an additional 10 ml blood sample at the same time as
venesection for routine pathology, and all samples were coded to
conceal the patients’ identity. The purity of enrichment ranged
between 83–91%. Cells (2610
5 cell ml
71) were washed and reset
in RPMI71640 medium supplemented with 10% FBS and 1% PS
and maintained at 378C in a humidiﬁed atmosphere with 5% CO2.
Cell mitogenic activity was stimulated with phytohaemagglutinin-
M (PHA-M; Sigma) at 20 mgm l
71. Following an initial 6-h incu-
bation, one of three drug combinations were added, STI571 alone
(4 mgm l
71); etoposide alone (0.5 mM); combination (4 mgm l
71
STI571 and 0.5 mM etoposide). Aliquots were removed daily for
analysis of cell proliferation and viability by Trypan blue analysis.
In addition, aliquots were removed on day 3 for clonogenic assays.
Haemopoietic clonogenic assays
Low-density mononuclear cells (MNC) from haematologically
normal donors, harvested through fractionation with Histopaque-
1077 (Sigma) and cells harvested from the preliminary ex vivo
suspension cultures were re-suspended in RPMI-1640 medium.
Cells (1610
5 cell ml
71) were plated in methylcellulose cultures
(Stem Cell Tech., USA) containing 0.9% methylcellulose and
30% FBS. Cultures were supplemented with a combination of
SCF (100 ng ml
71 – Amgen Ltd, Cambridge, UK), IL-3
(100 ng ml
71 – Sandoz Pharmaceuticals, Frimley, UK), GM-CSF
(50 ng ml
71 – Sandoz) and EPO (2 U ml
71 Janssen-Cilag Ltd,
High Wycombe, UK). Culture dishes were incubated at 378Ci n
a humidiﬁed atmosphere with 5% CO2. Colony formation was
assessed and typed after 14-days according to published methods
(Eaves and Eaves, 1984).
DNA analysis
The distinct phases of the cell cycle were distinguished by ﬂow
cytometry. Cells were washed in ice-cold nucleus buffer (0.15 M
NaCl, 5 mM MgCl2,1m M KH2PO4,1m M EGTA, 0.1 mM Dithio-
threitol, 10% glycerol in distilled water pH 6.5). Cells (1610
6)
were re-suspended in 4 ml of freshly constituted permeabilising
solution (0.35% Triton X-100, 0.1 mM PMSF in nucleus buffer),
and mixed by rotation at 48C for 20 min. Cells were then ﬁxed
by adding 4 ml of ice-cold methanol and rotated for a further
30 min. Samples were washed with ice-cold PBS before staining
with 500 ml of PI stain (50 mgm l
71 propidium iodide and
50 mgm l
71 RNAse A in PBS). Acquisition of data was performed
within 1 h using a Becton Dickinson FACScan machine. Ten thou-
sand cells were analysed for each data point, and the percentages of
cells in sub-G1 (apoptotic fraction), G1, S and G2/M phases were
analysed using a cell cycle analysis program (WinMDI 2.4).
Assessment of p21
waf1 by immunoblot analysis
Whole cell lysates were resolved by SDS–PAGE using 15% acry-
lamide with a 5% stacking gel as described previously (Liu et al,
2002). Brieﬂy, primary antibody probing was performed with
mouse-anti-p21
waf1 at a concentration of 0.2 mgm l
71 (PharMin-
gen). Mouse anti-b-actin was used as a loading control
(1:2000, Oncogene Research Products, Boston, USA). Following
a washing step in 0.1% Tween in tris buffered saline (Sigma,
100 mM Tris, 150 mM NaCl, pH 7.6), horseradish peroxidase-
conjugated anti-mouse IgG was used as the secondary antibody
(DAKO Ltd, High Wycombe, UK). Bands were visualised by the
ECL plus detection system (Amersham Life Science Ltd, Little
Chalfont, UK).
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All statistical analyses were carried out using Minitab version 10
(State College, PA, USA). Control samples were normally distribu-
ted as determined by the Shapiro-Wilk test, and parametric tests
were used throughout. Any difference between variables and
control cultures, as determined by ANOVA, were further charac-
terised by the standard paired Student’s t-test.
The concentration of any of the tested agents required to cause a
50% reduction in cell viability or cell number was determined with
an adapted version of the sigmoid Emax model as shown:
EP  EC ÿ
8
:Emax  Cn
ICn
50  Cn
9
; 2
where EP=predicted effect; EC=control effect; Emax=maximum
effect; C=concentration of drug; n=sigmoid-ﬁt factor (Holford
and Sheiner, 1981).
RESULTS
The percentage viability of cells in control cultures was 488% at
all time points. Separate experiments in stem cells harvested from
the bone marrow of haematologically normal volunteers revealed
that optimal colony formation was achieved using a SCF, IL-3,
GM–CSF and EPO cocktail, consequently, all short-term cultures
utilised this combination (McGuckin et al, 1996).
STI571 reduces the viability of CML-derived cell lines
A concentration and duration-dependent reduction in the rate of
cell proliferation expressed as a population doubling (PD), was
observed in both cell lines cultured with STI571 continuously for
5 days (Figure 1A). A decrease in viability, which reached signiﬁ-
cance at the higher concentrations and durations in both cell lines,
mirrored this reduction in PD (Figure 1B). The concentration of
the STI571 resulting in 50% reduction in per cent viability on day
5 (IC50) was calculated to be 4.9 mgm l
71 (&8.4 mM) and
3.5 mgm l
71 (&5.9 mM) for K562 and KU812 respectively.
Flow cytometric analysis showed an increased number of cells
undergoing apoptosis in cultures with STI571, with concomitant
reductions in the other phases of the cell cycle. This was most
clearly demonstrated in K562 cells treated with 5 mgm l
71
STI571 (Figure 2)
STI571 increases the cytotoxic effect of etoposide in K562
and KU812 cells
In K562 cells, single-agent etoposide (0.8 mM) had no cytotoxic
effect at any time throughout the 5 day culture. Instead, a cyto-
static response was seen, as indicated by a reduction in the rate
of PD by day 2 (day 2: 0.8+0.5 vs 1.9+0.4 in control cells;
P50.001) (Figure 3), and an increasing block in G2 phase of the
cell cycle. As described in the previous section, the continuous
exposure of K562 cells to STI571 resulted in a signiﬁcant reduction
in per cent viability by day 3. Most interestingly, the combination
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Figure 1 (A) Effect of STI571 on PD in K562 (left) and KU812 (right) cells. Points represent the mean and s.d. of three separate experiments. (B) Effect
of STI571 on per cent viability K562 (left) and KU812 (right) cells. Points represent the means and s.d. of three separate experiments.
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with greater reduction in cell viability than expected. This was
clearly demonstrated by comparing the total per cent viability in
cultures with a combination of STI571 and etoposide with the
numerical sum of per cent viability in cultures with the two drugs
separately (Figure 4). As an example, on day 5, per cent viability in
K562 cells cultured with etoposide alone was 95.8%, and 55.5%
with STI571 alone. Numerically, the decrease in per cent viability
in cells cultured with a combination of these two drugs would
be 48.7%, resulting in an expected per cent viability of 51.3%,
the sum of the viabilities. However, the observed per cent viability
of cultures with both drugs was 9.9%, indicating a hyper-additive
(synergistic) effect (P50.05).
Results in KU812 cells showed essentially the same pattern of
response, with signiﬁcantly decreased cell viability in cells treated
with a combination of both etoposide and STI571 compared to
the drugs individually (per cent viability on day 5: 34.1+1.4 vs
95.9+3.7 and 50.0+3.8% respectively; P50.001).
Subsequent ﬂow cytometric analysis in these cells indicated cell
kill to be partially by apoptosis as there was a concomitant increase
in %A. Parenthetically, %A on day 5 in K562: 5.0+1.8, 32.9+5.7
and 38.0+5.9% in etoposide alone, STI571 alone and in combina-
tion, respectively (KU812 results shown in Figure 5). Interestingly,
the block in the G2 phase of the cell cycle as seen in cultures with
etoposide alone was clearly absent in cultures containing both
etoposide and STI571 (Figure 5).
p21
waf1 levels are not increased in STI571-treated K562 cells
Whole cell lysates from K562 cells treated with STI571 alone and in
combination with etoposide were separated by electrophoresis, and
then immunoprobed for p21
waf1 protein. Results indicated
increased levels in cells cultured with etoposide alone but not in
the other samples. This pattern of p21
waf1 expression and drug-
combination was seen consistently on days 3–5 (Figure 6).
STI571 increases the cytotoxic effect of cytarabine in K562
and KU812 cells
The results seen in K562 and KU812 cells were essentially the same,
so only results from K562 experiments are presented. Cytarabine
alone had no signiﬁcant effect on cell viability over the 5-day peri-
od (per cent viability day 5: 94.6+3.6 vs 97.6+0.8% in control
cells), however, the combination of cytarabine with STI571
produced a signiﬁcant increase in the loss of viability compared
to just STI571 alone (P50.001) (Table 1).
STI571 reduces the viability of CD34
+ CML blast cells
Figure 7 highlights the effect of etoposide and STI571 on cell
proliferation and viability in CD34
+ CML blast cells.
In accordance with previous results from our in vitro experi-
ments, etoposide had a cytostatic effect as indicated by an
inhibition of cell proliferation, with only small decreases in PD.
Conversely, in cultures with STI571 alone, there was a reduction
in cell number and a concomitant duration dependent decrease
in per cent viability. Most notably, however, there was a greater
loss of viability in cells treated with both drugs compared with
etoposide or STI571 alone, which correlated with the cell line data.
A synergistic effect was seen between STI571 and etoposide, as
comparison of the difference in per cent cell kill in cultures using
the drugs simultaneously with the expected value, revealed consis-
tently more per cent cell kill in the former (difference in cell kill on
days 1, 2 and 3:
+6.9+5.5,
+12.2+7.8 and
+11.4+6.9% respec-
tively), which was signiﬁcant on days 2 and 3 (P=0.05)
STI571 increases the colony forming potential of CML blast
cells
CD34
+ CML cells that were cultured with drugs for 3 days were
plated in short-term semi-solid cultures supplemented with a cock-
tail of GFs. Colony formation was typed and enumerated on day
14. This allowed for an assessment of the effect of STI571 on
surviving progenitors following culture in suspension.
The total number of colony and burst forming units (CFUs and
BFUs) developing from the blast cells of haematologically normal
volunteers cultured with GFs had been previously assessed as
171.5+6.7, and the distribution of colony type was evenly divided
between myeloid and erythroid (45.5% CFU-G, 10.5% CFU-M,
3.2% CFU-GM, 40.7% BFU-e). In control plates of CML cells with
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Figure 2 Effect of 5 mgm l
-1 STI571 on cell cycle distribution over 5-days
in K562 cells. Points represent the means and s.d. of four separate experi-
ments.
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colony forming), and only 47.0+6.4 observable colonies that were
exclusively of the CFU-G type. A similar pattern of cell and colony
proliferation was seen in PHA-M-stimulated blast cells that had
been treated with etoposide alone of just 41.7+3.5 colonies
(97.9% CFU-G).
Most interestingly, those cultures of cells that had been treated
with STI571 alone showed increased numbers of colony forming
cells, with a total of 62.7+2.1 colonies that was also made up of
non-CFU-G types (81.9% CFU-G, 13.9% CFU-M, 4.1% CFU-
GM). Cells treated with both drugs produced a total colony count
that was signiﬁcantly higher than controls, but similar to those
with STI571 alone (66.7+8.5 vs 47.0+6.4 and 62.7+2.1 respec-
tively; P50.001 in the former comparison). Additionally, there
was a lower ratio of CFU-G to non-CFU-G colonies produced
from these cells compared to cells treated with STI571 alone
(66.1% CFU-G, 21.6% CFU-M, and 12.3% CFU-GM) (P=0.07).
DISCUSSION
We have previously shown the CML-derived cell lines K562 and
KU812 to be resistant to a range of drugs. Although the exact
mechanism of this resistance has yet to be fully elucidated, there
is strong evidence suggesting that the constitutive expression of
BCR–ABL protein TK in these cell lines contributes to the pheno-
type. This study was therefore undertaken to investigate the
importance of functional BCR–ABL TK in determining the sensi-
tivity of CML-derived cell lines to anti-cancer agents. To this end,
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Figure 6 p21 levels in K562 cells treated with etoposide alone (lanes: 2, 6, 10), STI571 alone (lanes: 3, 7, 11) or a combination of the two (lanes: 4, 8, 12).
Cells were treated continuously for 5 days. Samples from day 3 (lanes: 1–4), day 4 (lanes: 5–8) and day 5 (lanes: 9–12) are shown, with respective controls
(lanes: 1, 5, 9).
Table 1 Effect of STI571 and 40 nM cytarabine (araC) on %V and PD in K562 cells on days
3, 4 and 5
Population doubling Percentage viability
345345
Control 2.3+0.3 2.8+0.3 3.2+0.2 97.0+1.8 97.6+1.0 97.6+0.8
araC 0.6+0.1 0.6+0.1 0.7+0.1 92.2+5.2 92.1+3.0 94.6+3.6
STI571 70.2+0.5 70.6+0.7 70.9+0.8 69.5+8.9 60.9+8.8 53.9+9.8
Comb. 70.6+0.3 71.3+0.3 72.0+0.4 38.4+8.6* 38.4+8.1* 25.7+7.2*
Data represent the means and s.d.s of ﬁve separate experiments. *P50.001 compared to STI571 alone.
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+ blast cells harvested from CML patients,
were cultured with a TK inhibitor (STI571) both alone and in
combination with other anti-leukaemic agents. Not only did we
show in cell lines and in blast cells that STI571 was an effective
cytotoxic as a single agent, but we also showed synergistic interac-
tion with etoposide and cytarabine.
In the ﬁrst part of our investigation, we determined the effect of
a continuous exposure to STI571 on cell proliferation and viability
in K562 and KU812 cell lines. Calculation of IC50 suggested KU812
to be possibly more sensitive to STI571 than K562 (5.9 mM vs
8.4 mM). Results indicated clear concentration and duration depen-
dent decreases in cell viability in both cell lines. Additionally,
subsequent ﬂow cytometric analysis showed that cell kill was by
apoptosis, occurring from all phases of the cell cycle. These IC-
values were higher than those reported in recent synergy studies
(Thiesing et al, 2000; Kano et al, 2001; Topaly et al, 2001). Meth-
odologically, the activity of STI571 in combination in these studies
was assessed by the MTT assay, which is strictly a technique for
measuring cell number and not cell kill (Carmichael et al, 1987).
Consequently, as the assay cannot distinguish between cytostasis
and cytotoxicity, these two distinct processes are grouped as the
same, resulting in a greater level of activity than would otherwise
have been seen if viability was measured exclusively (Hoffman,
1991).
We next investigated the effect of combining STI571 with the
anti-leukaemic agents etoposide and cytarabine in both K562
and KU812. The effect of culturing cells with either agent alone
was solely one of cytostasis. However, the culture of cells with
either drug in combination with STI571 resulted in increased
apoptosis and signiﬁcantly reduced cell viability. In particular,
the expected block in G2/M induced by both etoposide and cytar-
abine was not seen in cells when cultured with STI571 and either
drug. As the level of p21
waf1 expression is important in mediating
this G2/M block and in predicting cytotoxicity (Liu et al, 2002),
the levels of this protein were assessed in K562 cells. Interestingly,
the levels in cells cultured with STI571, either alone or in combi-
nation with other cytotoxics, was unchanged from that seen in
controls.
Following the results of our cell line experiments, the effect of
STI571 on cell growth was modelled and studied further in
CML-derived blast cells. CD34
+ mononuclear progenitor stem cells
(PSCs) were harvested from the peripheral blood of CML patients,
mitogenically stimulated, and then cultured for 3-days in the
presence of STI571, etoposide or a combination of the two. As with
the cell line studies, there was a duration dependent decrease in cell
viability in PSCs cultures treated with STI571 alone. Also, in accor-
dance with cell line data, etoposide had a cytostatic effect on PSCs,
with viability remaining relatively high. Most importantly, the
combination of STI571 with etoposide also showed a greater reduc-
tion in cell viability compared to either of the drugs alone.
Mechanistically, STI571 has been shown to inhibit Akt kinase
through its interactions with BCR–ABL (Fang et al, 2000). Akt
kinase is a key component of the apoptotic cascade, and can inter-
act at many stages. It has been shown to phosphorylate and
inactivate BAD (Datta et al, 1999), by converting it to an inactive
moiety that is bound to the cytosol, and is therefore unable to
hetero-dimerise with BCL-2 and BCL-XL (Yang et al, 1995). Cell
survival signals are thus promoted. Akt kinase has also been shown
to directly phosphorylate and inactivate caspase-9, thereby prevent-
ing the activation of the executioner caspases (Cardone et al, 1998).
Consequently, the inhibition of Akt kinase can result in a sensitisa-
tion of cells to apoptosis by existing chemotherapeutic agents by
down-regulating BCL-XL and enhancing the caspase cascade.
To further characterise the effects of STI571 on PSCs, the clono-
genicity of the surviving fraction of committed progenitor cells
were analysed in colony-forming assays. A hallmark of CML is
the expansion of immature progenitor cells of the myeloid lineage
in the bone marrow compartment, so that the majority of periph-
eral circulating CD34
+ cells from CML patients are myeloid
(Fialkow et al, 1977). PSCs were harvested from suspension
cultures, washed and plated on semi-solid methylcellulose plates
supplemented with a cocktail of GFs conducive to erythroid colony
formation (McGuckin et al, 1996). Results were similar to those of
Thiesing et al (2000), and showed that although there was a large
number of cells seen on the culture plates, most lacked clonogenic
capability since only a small number of colonies were seen. As
expected of blast cells from CML patients with abnormal haemo-
poiesis, there was a reduction in the total number of colonies,
which were all of the CFU-G class. The intrinsic nature of etopo-
side cytotoxicity, which is dependent upon the levels of the nuclear
enzyme topo II (Zwelling, 1985), would have an equal effect in
both the normal and abnormal surviving PSCs. This was reﬂected
in our clonogenic assays that were essentially the same as those
seen in control cultures with no added drug, having only CFU-G
colonies present. Interestingly, the culture of PSCs that had been
treated with STI571 resulted in an overall increase in the total
number and heterogeneity of colonies, indicating the presence of
a surviving fraction of normal haemopoietic progenitor cells and
thus some drug speciﬁcity. The combination of STI571 and etopo-
side produced even greater numbers of non-CFU-G colonies,
indicating an advantage of co-culture with existing cytotoxics.
Overall, our ﬁndings are in general agreement with similar
reports of drug interactions between STI571 and anti-leukaemic
agents that have been published in the last year (Thiesing et al,
2000; Kano et al, 2001; Topaly et al, 2001). While these studies only
stopped at highlighting a synergistic reduction in absolute cell
number, we went on to speciﬁcally identify hyper-additive increases
in apoptosis. In the present study, we only used simultaneous expo-
sure to both STI571 and other agents. Numerous reports have
highlighted the importance of drug scheduling in determining the
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of agents that act on speciﬁc phases of the cell cycle can be improved
by a sequential administration with STI571 (Mani et al, 2000;
Senderowicz, 2001). Having demonstrated a synergistic beneﬁt of
the co-administration of STI571 with other anti-leukaemic agents,
further studies are required to elucidate the precise mechanism of
this enhancement, so that its application may be fully maximised.
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